Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026

Grace Therapeutics, Inc.

2025-Q2 EPS reported -$0.53 vs consensus -$0.22 ▼ miss (-136.2%)

Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.
Phase 3 STRIVE-ON safety trial enrollment complete; data readout expected Q1 2025; NDA submission for GTx-104 on track for 1H 2025.
Cash and equivalents $15.1M; projected runway into Q2 2026.
Redomiciled to Delaware and rebranded to Grace Therapeutics; ticker changed to GRCE on Nasdaq.
Hosting KOL event on aSAH on Nov 20, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.